BioMarin Alesta Therapeutics Acquisition: BioMarin Acquires Alesta to Secure Oral HPP Candidate ALE1 for $275M Upfront
The BioMarin Alesta Therapeutics acquisition secures lead oral asset ALE1 for $275M upfront plus milestones, expanding BioMarin’s rare disease skeletal pipeline.
